Target intelligence / Profile preview

Platelet dense granule secretion machinery

Molecular classification
SNARE complex, Protein complex, Exocytosis machinery
01

Overview

The platelet dense granule secretion machinery is a specialized multi-protein complex that facilitates the exocytosis of dense granules (delta-granules), which store critical mediators such as serotonin, ADP, and calcium. The core of this machinery is the SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor) complex, primarily composed of the vesicle-SNARE VAMP-8 and the target-SNAREs Syntaxin-11 and SNAP-23 (Flaumenhaft, 2003; Ren et al., 2007). Regulatory proteins, including Munc13-4 and Rab27, are essential for the docking and priming of these granules at the plasma membrane or the open canalicular system (Shirakawa et al., 2004). Upon platelet activation by agonists like thrombin or collagen, this machinery triggers the rapid release of serotonin, which acts as a paracrine signal to amplify platelet recruitment and induce local vasoconstriction (Heijnen & van der Sluijs, 2015). Dysfunction of this machinery leads to bleeding disorders such as Hermansky-Pudlak syndrome, while overactivity contributes to pathological thrombosis. While current antiplatelet drugs like aspirin indirectly reduce secretion by blocking upstream signaling, novel therapeutic strategies are exploring the direct targeting of SNARE proteins to more precisely control platelet reactivity (Ye et al., 2012).

Other names
Platelet exocytosis machineryPlatelet secretion apparatusDense granule release machinerySNARE-mediated serotonin release
02

Mechanism of action

Inhibition of agonist-induced signaling pathways (e.g., COX-1 or P2Y12 inhibition) that trigger granule release, or direct interference with SNARE-mediated membrane fusion using peptide mimetics.

03

Biological functions

ExocytosisPlatelet activationHemostasisSerotonin releaseVesicle trafficking
04

Disease associations

Cardiovascular diseaseThrombosisBleeding disordersHermansky-Pudlak syndromeChediak-Higashi syndrome
05

Safety considerations

Increased bleeding riskImpaired wound healingPotential for systemic exocytosis inhibition in other cell types
06

Interacting drugs

Aspirin

6 more in the full profile.

07

Biomarkers

CD63 (LAMP-3)Serotonin (5-HT) releaseATP releaseP-selectin (CD62P)

Beyond the preview

Go deeper on Platelet dense granule secretion machinery.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Platelet dense granule secretion machinery.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call